. home.aspx



4BIO Capital Raises €45M Fund to Invest in Advanced Therapies

September 09, 2019 / JONATHAN SMITH

The London-based life sciences investor 4BIO Capital has raised €45M in the first close of a fund to nurture companies developing advanced therapies such as gene and cell therapies. This is the first closing of 4BIO’s second fund, called 4BIO Ventures II, which is expected to total €136M ($150M) by late 2020. The fund will invest in up to 12 companies around the world that are developing advanced therapies such as cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. 4BIO expects to make the first investment from this fund in the next few months. One-third of the funds will be dedicated to establishing new companies, with 4BIO getting involved in tasks such as selecting the leadership team and preparing licensing documents. The rest will be invested in seed and Series A rounds, with an average investment of around €8M per company. One of the main advanced therapies in 4BIO’s focus is gene therapy. Most gene therapies currently targ...